— Know what they know.
/
Not Investment Advice

HUM

NYSE · USD
Humana Inc.
Healthcare · Medical - Healthcare Plans
CEO James A. Rechtin Employees 67,060 R&D / revenue 0.0%
Last price
$413.33−4.37%last session
Market cap
$49.6B
P/E (TTM)
38.8x
From 52w high
−9.5%
From 52w low
+153.4%
1-year return
+54.6%
RSI 14 · vs SMA200
54.3 · +37.3%
IS score
26.5/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

HUM   SPY   XLV (sector ETF) · weekly closes
6080100120140160Jan 26Apr 26Jul 26Oct 26HUM 155XLV 124SPY 116

Score DNA

Each bar is a 0-100 score within the scored universe
15
Profitability
40
Growth
45
Value
33
Momentum
100
Risk (safety)
35
Quality
70
Balance sheet
60
Earnings quality

Flags

Strengths
✓ Net cash✓ Congress buying
Warnings
▲ Beneish M above -1.78▲ Negative free cash flow▲ Share count rising
Observations
Moat model: Weak, Efficient ScalePiotroski 4 / 9Altman Z 4.6Beta 0.743 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
0
No open-market sales on file
No Form 144 notices in 12 months
CONGSTOCK Act · 180 days
Congressional purchases
1
Last disclosed purchase 2026-03-27
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
+144
242 new holders, 93 closed
933 filers hold 99.7% · 321 added, 268 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+210
1,202 funds adding shares
992 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
52.1%
20-day avg 51.2%, 50-day avg 51.8%
Latest 0.9 pp over its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$129.7B
Revenue growth YoY+10.1%
Gross margin14.5%
Operating income$1.5B
Operating margin1.1%
Net income$1.2B
Net margin0.9%
EPS (diluted)$9.84
Cash flow
Operating cash flow$921.0M
Capital expenditure$546.0M
Free cash flow$375.0M
FCF conversion (FCF / OCF)40.7%
Stock-based compensation$241.0M
FCF less SBC$134.0M
Buybacks$151.0M
Dividends$430.0M
Balance sheet & returns
Cash & short-term investments$4.2B
Total debt$12.5B
Net debt$8.3B
Shareholders' equity$17.7B
Goodwill & intangibles$10.8B
Debt / equity0.74
ROE (TTM)6.9%
ROIC (TTM)4.5%
Operating margin by fiscal year
4.0%FY20213.8%FY20223.2%FY20231.5%FY20241.2%FY2025
Revenue $83.1B (FY2021) to $129.7B (FY2025), a 11.8% CAGR.

Valuation

P/E (TTM)38.8x
EV / EBITDA18.4x
Price / sales0.34x
Price / FCFn/m
FCF yield-0.89%
Buyback yield0.30%
SBC / revenue0.2%
Price / book2.59x
Forward P/E FY202645.1x
Forward P/E FY202724.4x
Forward P/E FY202813.5x
Forward multiples divide today's price by Street EPS estimates. Street mean target $477.18 across 22 analysts last quarter is theirs, not ours.

HUM vs industry median

19 companies in Medical - Healthcare Plans
Gross margin 13.7% 22.4% Operating margin 1.4% 3.8% Net margin 0.9% 2.6% ROIC 4.5% 11.8%
HUM (TTM)Industry median Asset turnover 2.55 vs industry 1.74 · financial leverage 2.98

Earnings delivery

Next report 2026-11-06 · consensus EPS $-1.00
92%
beat rate, 11 of 12 quarters
+7.3%
median EPS surprise
10
longest beat streak
+9-57+18+19+22+3+15+6+11+1+1+5
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-11-01 to 2026-07-29. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
HUM Humana Inc. $49.6B38.8x6.9%0.9%+10.1% +54.6%
CNC Centene Corp. $34.2Bn/m-20.4%2.5%+8.7% +94.0%
CI Cigna Corporation $79.9B12.5x15.5%2.3%+7.7% +4.5%
ELV Elevance Health Inc. $92.9B19.0x11.2%2.9%+6.3% +23.6%
CVS CVS Health Corp. $118.1B24.1x6.2%2.8%+7.4% +14.4%
MOH Molina Healthcare, Inc. $10.8B1,296.0x-0.2%0.6%+2.6% —
OSCR Oscar Health, Inc. $8.3B18.6x34.3%7.4%+42.8% —
UNH UnitedHealth Group Incorpora $360.3B22.9x15.9%3.6%+3.3% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-10-13Regulation FD; Exhibits
2026-10-09Regulation FD
2026-09-01Regulation FD
2026-07-29Earnings Release; Regulation FD; Exhibits
2026-07-29Officer/Director Change; Exhibits
2026-06-01Regulation FD

Context

Shares outstanding120,080,000
Free float99.8%
Institutional ownership99.7%
Beta0.74
Dividend yield0.86%
Last dividend$0.89 on 2026-10-30
50 / 200-day average$393.00 / $300.29
Large-cap Healthcare median P/E29.7x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Weak).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where HUM sits among 11 scored companies in Medical - Healthcare Plans (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasureHUMIndustry medianIndustry percentileSector median
P/E (TTM) 38.8x 23.4x
86th		 27.6x
PEG (P/E ÷ 3-yr EPS CAGR) —
Price / sales 0.3x 0.4x
40th		 3.7x
Price / book 2.6x 2.6x
40th		 3.6x
Price / tangible book 5.5x 5.5x
38th		 5.8x
Price / free cash flow —
Price / operating cash flow 337.6x 8.4x
100th		 17.1x
Enterprise value $40.0B $23.2B
60th		 $2.5B
EV / sales 0.3x 0.4x
30th		 3.8x
EV / EBITDA 12.9x 13.5x
38th		 16.2x
EV / EBIT 17.3x 17.1x
62nd		 23.0x
EV / free cash flow —
Earnings yield 2.6% 3.8%
40th		 -0.3%
FCF yield -0.9% 10.0%
0th		 1.7%
Operating cash flow yield 0.3% 11.8%
0th		 2.9%
Graham number (per share) $194.43 $133.77
57th		 $26.70

Profitability (TTM)

MeasureHUMIndustry medianIndustry percentileSector median
Gross margin 13.7% 16.1%
30th		 65.1%
EBITDA margin 2.1% 3.2%
40th		 6.6%
Operating margin 1.4% 2.0%
40th		 3.5%
EBIT margin 1.6% 2.1%
40th		 2.4%
Net margin 0.9% 1.2%
30th		 0.3%
NOPAT margin 1.1% 1.7%
30th		 2.7%
FCF margin -0.3% 3.2%
0th		 4.3%
Operating cash flow margin 0.1% 3.7%
0th		 7.1%
R&D / revenue 0.0% 0.0%
0th		 12.4%
SG&A / revenue 2.7% 6.8%
10th		 37.9%
Stock comp / revenue 0.2% 0.2%
40th		 4.5%
Effective tax rate 18.5% 17.8%
60th		 21.0%

Returns on capital

MeasureHUMIndustry medianIndustry percentileSector median
ROE (on average equity) 6.8% 11.2%
40th		 0.8%
ROA 2.4% 3.6%
40th		 -0.3%
ROIC 17.2% 4.9%
90th		 5.5%
ROCE 6.8% 7.5%
40th		 2.3%
Return on tangible assets 4.3% 4.8%
40th		 1.7%
Cash ROIC (OCF / invested capital) 1.5% 18.5%
0th		 9.7%
Gross profitability (GP / assets) 34.8% 37.6%
40th		 29.9%
ROIC, 3-yr average —
ROIC, 5-yr average -118.6% 6.3%
0th		 3.2%
ROE, 5-yr average 13.2% 12.6%
60th		 -4.9%
Incremental ROIC 14.0% 71.5%
20th		 17.2%

Growth

MeasureHUMIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) 18.3% 7.7%
70th		 10.5%
Revenue growth (QoQ) 3.1% 3.1%
50th		 7.2%
Revenue CAGR, 3 yr 13.8% 10.9%
70th		 10.7%
Revenue CAGR, 5 yr 12.6% 12.6%
50th		 12.1%
Gross profit CAGR, 3 yr -41.4% 10.9%
0th		 10.6%
Operating income CAGR, 3 yr -21.0% -5.4%
17th		 11.7%
Net income growth (TTM YoY) -18.9% 0.4%
0th		 17.5%
Net income CAGR, 3 yr -27.7% -4.7%
0th		 11.3%
EPS growth (TTM YoY) -19.0% 1.6%
0th		 19.2%
EPS CAGR, 3 yr -26.8% -1.4%
0th		 14.0%
EPS CAGR, 5 yr -11.2% 1.2%
0th		 8.1%
FCF growth (TTM YoY) —
FCF CAGR, 3 yr —
Operating cash flow CAGR, 3 yr -77.7% -4.1%
0th		 11.9%
Book value CAGR, 3 yr 5.7% 5.7%
50th		 2.1%
Dividend CAGR, 3 yr 1.2% 2.6%
25th		 2.2%
Sustainable growth rate 4.5% 9.7%
14th		 12.2%

Margin history & stability

MeasureHUMIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 71.2% 21.2%
80th		 62.6%
Operating margin, 3-yr average 1.8% 2.6%
40th		 1.0%
Net margin, 3-yr average 1.2% 1.4%
40th		 -2.6%
FCF margin, 3-yr average -0.9% 2.1%
20th		 3.2%
Revenue stability (0-1) 0.97 0.97
50th		 0.80
Earnings stability (0-1) 0.58 0.24
90th		 0.37
Margin stability (0-1) 0.53 0.83
10th		 0.93

Liquidity (latest quarter)

MeasureHUMIndustry medianIndustry percentileSector median
Cash & short-term investments $23.9B $8.9B
70th		 $330.9M
Net cash (− = net debt) $9.6B $371.2M
90th		 $8.4M
Working capital $17.1B $477.0M
90th		 $381.1M
Current ratio 1.74 1.50
80th		 3.02
Quick ratio 1.74 1.50
80th		 2.51
Cash ratio (cash + ST investments / current liabilities) 1.04 0.98
80th		 1.43
Defensive interval (days) 604 days 521 days
70th		 415 days

Leverage & solvency (latest quarter)

MeasureHUMIndustry medianIndustry percentileSector median
Total debt $14.2B $14.2B
50th		 $289.1M
Debt / equity 0.74 0.71
60th		 0.45
Net debt / equity −0.50 −0.49
40th		 −0.13
Debt / assets 24.9% 23.8%
80th		 24.4%
Debt / capital 42.6% 41.7%
60th		 31.1%
Debt / EBITDA 4.60 3.76
75th		 2.62
Net debt / EBITDA −3.11 −1.65
38th		 1.42
Interest coverage (EBIT / interest) 3.3x 3.4x
38th		 2.1x
Cash interest coverage 0.2x 6.8x
0th		 3.6x
Debt payback (years of OCF) 96.9 yrs 2.8 yrs
100th		 2.7 yrs
Liabilities / assets 66.3% 68.5%
40th		 49.8%
IS credit model rating A- — —
Implied credit spread (bps) 175 150
60th		 225

Efficiency

MeasureHUMIndustry medianIndustry percentileSector median
Asset turnover 2.71 1.83
70th		 0.56
Fixed asset turnover 69.44 72.51
44th		 4.87
Inventory turnover —
Receivables turnover 28.6 15.8
90th		 6.4
Days sales outstanding 13 days 23 days
10th		 57 days
Days inventory outstanding —
Days payables outstanding 19 days 35 days
30th		 59 days
Cash conversion cycle (days) −6 days 2 days
40th		 70 days
Capex / revenue 0.4% 0.4%
40th		 2.6%
Capex / depreciation 0.76 0.76
50th		 0.55
Operating expense ratio 10.1% 13.7%
20th		 56.5%

Cash flow & earnings quality

MeasureHUMIndustry medianIndustry percentileSector median
Operating cash flow / net income 0.12 2.33
0th		 1.61
FCF / net income −0.35 1.92
0th		 1.36
FCF / operating cash flow -301.4% 88.0%
0th		 81.2%
Capex / operating cash flow 401.4% 12.0%
100th		 18.8%
Accruals ratio 2.1% -3.9%
100th		 -5.4%
Sloan accruals ratio 30.3% 0.9%
100th		 -1.3%
Earnings quality score (0-1) 0.25 0.88
0th		 0.75

Dividends & buybacks

MeasureHUMIndustry medianIndustry percentileSector median
Dividend yield 0.9% 0.0%
60th		 0.0%
Dividend per share (TTM) $3.54 $0.00
70th		 $0.00
Payout ratio (dividends / net income) 33.6% 27.8%
71st		 0.0%
Dividends / FCF —
Dividend growth (YoY) 0.1% 2.6%
25th		 4.5%
Buyback yield 0.3% 0.6%
40th		 0.0%
Shareholder yield (dividends + buybacks) 1.2% 2.9%
40th		 0.0%
Share count change (YoY) 0.1% 0.1%
50th		 2.0%
Buybacks, last 5 years $868.0M $772.4M
60th		 $0

Scores & forensic checks

MeasureHUMIndustry medianIndustry percentileSector median
IS score 27 55
0th		 46
IS profitability 15 27
30th		 22
IS growth 40 50
40th		 60
IS value 45 45
50th		 39
IS momentum 33 79
0th		 67
IS risk (safety) 100 80
60th		 80
IS quality 35 67
0th		 49
IS balance sheet 70 62
60th		 55
IS earnings quality 60 65
40th		 56
IS cash flow 2 61
0th		 41
Piotroski F-score (0-9) 4 7
0th		 5
Altman Z-score 4.6 3.1
80th		 3.2
Beneish M-score 0.99 −2.82
100th		 −2.62
Ohlson O-score −7.79 −7.59
40th		 −7.16
IS credit score 66 74
40th		 62

Per share

MeasureHUMIndustry medianIndustry percentileSector median
EPS, diluted (TTM) $10.57 $1.65
70th		 −$0.03
Book value per share $158.93 $62.12
80th		 $7.10
Tangible book per share $73.15 $6.80
90th		 $1.91
Revenue per share $1,205.02 $389.31
100th		 $9.38
FCF per share −$3.66 $9.16
0th		 $0.46
Operating cash flow per share $1.22 $11.52
20th		 $0.93
Cash per share $197.46 $25.66
100th		 $3.51

Size (TTM)

MeasureHUMIndustry medianIndustry percentileSector median
Market cap $49.6B $34.2B
60th		 $2.4B
Revenue $145.7B $145.7B
50th		 $770.2M
EBITDA $3.1B $633.7M
60th		 $56.1M
Net income $1.3B $550.7M
60th		 −$3.3M
Free cash flow −$443.0M $4.3B
0th		 $41.2M
Total assets $57.2B $57.2B
50th		 $1.3B
Shareholders' equity $19.2B $19.2B
50th		 $568.4M
Employees 67,060 61,100
70th		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-09-30Hilzinger Kurt J
Director
 Award / grant 238——16,772
2026-09-01Nundy Shantanu
Chief Medical Officer
 Award / grant 2,549——2,549
2026-08-01Crawford Frederick John
Director
 Award / grant 544——544
2026-08-01Smith Paul John
Director
 Award / grant 544——544
2026-06-30Hilzinger Kurt J
Director
 Award / grant 233——16,534
2026-05-01Mellet Celeste
Chief Financial Officer
 Award / grant 15,387——39,637
2026-05-01Mehta Japan
Chief Information Officer
 Award / grant 9,448——17,176
2026-05-01Dintenfass David
President, Enterprise Growth
 Award / grant 11,273——25,407
2026-05-01Rechtin James A.
President & CEO
 Award / grant 35,633——63,938
2026-05-01O'Hara Michelle A.
Chief Human Resources Officer
 Award / grant 10,485——20,026
2026-05-01Field Robert Stuart
Director
 Award / grant 852——852
2026-05-01Ventura Joseph C
Chief Legal Officer
 Award / grant 10,318——27,405

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
MarAprMayJunJulAugSep

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired13100,268—
Award / grantDisposed115,387—
—Disposed30—
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

FiledFilerShares proposedEst. proceeds
2025-04-08Diamond Susan M10,959$2.7M
2025-02-24Huval Timothy S.1,247$322,443
2024-12-31Huval Timothy S.3,703$938,433
2024-12-06William K. Fleming8,661$2.5M
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 14 trades (4 purchases) · Senate 1 (1 purchases)
TradedMemberChamberTypeAmountDisclosed
2026-04-10Michael McCaulHousePurchase$1,001 - $15,0002026-05-11
2026-04-10Michael T. McCaulHousePurchase$1,001 - $15,0002026-05-11
2026-03-27Alan ArmstrongSenatePurchase$1,001 - $15,0002026-07-20
2026-02-10Julia LetlowHouseSale$1,001 - $15,0002026-03-13
2026-02-10Julia LetlowHouseSale$1,001 - $15,0002026-03-13
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
DODGE & COX10,940,380$4.3B9.11%
BlackRock, Inc.10,417,803$4.1B8.68%
VANGUARD CAPITAL MANAGEMENT LLC7,843,620$3.1B6.53%
VANGUARD PORTFOLIO MANAGEMENT LLC5,818,956$2.3B4.85%
STATE STREET CORP5,457,072$2.2B4.54%
PZENA INVESTMENT MANAGEMENT LLC4,403,136$1.7B3.67%
Sessa Capital IM, L.P.3,727,740$1.5B3.10%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/3,578,245$1.7B2.98%
GEODE CAPITAL MANAGEMENT, LLC3,369,757$1.3B2.81%
FMR LLC2,913,763$1.2B2.43%
Capital International Investors2,392,826$950.5M1.99%
GOLDMAN SACHS GROUP INC2,299,889$913.6M1.92%
JPMORGAN CHASE & CO2,266,409$881.4M1.89%
NAYA CAPITAL MANAGEMENT UK LTD1,833,763$728.4M1.53%
NORGES BANK1,748,414$694.5M1.46%

Institutional ownership by quarter

2023-092026-0699.7%
% of shares held by 13F filers
2023-092026-06933
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-3093399.7%24232126893
2026-03-3178995.9%106249328167
2025-12-31865100.3%120264359127
2025-09-3089394.1%135330307111
2025-06-3088594.4%111322335120
2025-03-3190695.0%143323313107
2024-12-3188296.8%147274374191
2024-09-3094593.9%96324384123
2024-06-3098594.7%122341387154
2024-03-311,03691.4%122360421223
2023-12-311,16092.8%17340942490
2023-09-301,09194.9%12939640199

Schedule 13D / 13G filers

FiledFormFiler% of classShares
2026-04-30SCHEDULE 13GVanguard Capital Management7.5%9,068,300
2025-07-29SCHEDULE 13G/AThe Vanguard Group11.8%14,199,071
2025-04-17SCHEDULE 13G/ABlackRock, Inc.7.7%9,309,848
2025-02-13SCHEDULE 13GDodge & Cox8.5%10,198,040
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
VITSX0.06%$1.5B
VTSAX0.06%$1.5B
VTI0.06%$1.5B
VSMPX0.06%$1.5B
VFIAX0.07%$1.2B
VFINX0.07%$1.2B

Share structure

Shares outstanding120,080,000
Float119,825,738
Free float99.8%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$83.1B$92.9B$106.4B$117.8B$129.7B
Cost of revenue$0$0$0$0$110.8B
Gross profit$83.1B$92.9B$106.4B$117.8B$18.9B
R&D$0$0$0$0$0
SG&A$0$0$0$0$0
Operating income$3.4B$3.6B$3.4B$1.7B$1.5B
EBITDA$4.4B$4.8B$4.8B$3.3B$2.9B
Pretax income$3.4B$3.6B$3.3B$1.6B$1.5B
Income tax$485.0M$762.0M$836.0M$413.0M$250.0M
Net income$2.9B$2.8B$2.5B$1.2B$1.2B
EPS, diluted$22.67$22.08$20.00$9.98$9.84
Diluted shares129.4M127.1M124.4M120.9M120.8M

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$3.4B$5.1B$4.7B$2.2B$4.2B
Receivables$1.8B$1.7B$2.0B$2.7B$3.3B
Inventory$0$0$0$0$0
Total current assets$0$0$0$0$7.5B
PP&E, net$3.8B$3.7B$3.5B$3.0B$2.7B
Goodwill & intangibles$13.7B$10.9B$11.2B$11.1B$10.8B
Total assets$44.4B$43.1B$47.1B$46.5B$48.8B
Accounts payable$0$0$0$0$9.8B
Total current liabilities$0$0$0$0$10.3B
Long-term debt$10.5B$9.0B$10.2B$11.1B$12.4B
Total liabilities$28.3B$27.7B$30.7B$30.0B$31.0B
Shareholders' equity$16.1B$15.4B$16.3B$16.4B$17.7B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$2.9B$2.8B$2.5B$1.2B$1.2B
Depreciation & amortization$713.0M$845.0M$917.0M$968.0M$773.0M
Stock-based compensation$180.0M$216.0M$175.0M$207.0M$241.0M
Change in working capital−$556.0M$534.0M$81.0M$154.0M−$1.9B
Operating cash flow$2.3B$4.6B$4.0B$3.0B$921.0M
Capital expenditure−$1.3B−$1.1B−$1.0B−$575.0M−$546.0M
Free cash flow$920.0M$3.5B$3.0B$2.4B$375.0M
Investing cash flow−$6.6B−$1.0B−$3.5B−$3.0B$2.3B
Net debt issued / repaid$3.8B−$1.4B$423.0M$218.0M$533.0M
Buybacks−$79.0M−$2.1B−$1.6B−$817.0M−$151.0M
Dividends paid−$354.0M−$392.0M−$431.0M−$431.0M−$430.0M

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2021FY2022FY2023FY2024FY2025
Gross margin100.0%100.0%100.0%100.0%56.3%
Operating margin4.0%3.8%3.2%1.5%1.2%
Net margin3.5%3.0%2.3%1.0%0.9%
FCF margin1.1%3.7%2.8%2.0%0.3%
ROE19.7%17.9%15.8%7.4%7.0%
ROIC12.4%14.5%11.6%5.1%4.8%
ROA7.4%6.4%5.5%2.6%2.5%
Debt / equity0.660.590.630.680.73
Interest coverage11.3x9.9x7.9x3.6x3.4x
Current ratio————0.72
Revenue growth+7.7%+11.8%+14.5%+10.7%+10.1%
EPS growth−10.5%−2.1%−9.0%−50.8%−1.2%
P/E at year end19.6x22.3x22.0x25.1x25.9x
EV / EBITDA at year end14.7x13.8x12.6x11.7x13.3x
FCF yield at year end1.64%5.55%5.43%7.89%1.22%
Dividend payout12.1%14.0%17.3%35.7%36.2%

Revenue by segment

FY2021FY2022FY2023FY2024FY2025
Insurance Segment—$88.8B$102.9B$113.8B$124.6B
Retail Segment$74.0B————
Healthcare Services$31.2B————
CenterWell Segment—$17.3B$18.4B$19.9B$22.5B
Group And Specialty$6.9B————

Street estimates by fiscal year

Next report 2026-11-06 · consensus EPS $-1.00 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$162.5B$161.8B – $163.0B$9.16$9.04 – $9.611745.1x
2027$167.8B$159.2B – $177.3B$16.96$11.00 – $21.171624.4x
2028$180.4B$163.3B – $193.8B$30.52$24.40 – $40.47913.5x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-07-29$7.27$7.61+4.7%$40.6B$40.9B+0.7%
2026-04-29$10.24$10.31+0.7%$39.4B$39.6B+0.7%
2026-02-11$-4.00$-3.96+1.0%$32.0B$32.5B+1.5%
2025-11-05$2.93$3.24+10.6%$32.0B$32.6B+2.0%
2025-07-30$5.92$6.27+5.9%$31.9B$32.4B+1.6%
2025-04-30$10.07$11.58+15.0%$32.2B$32.1B−0.3%
2025-02-11$-2.23$-2.16+3.1%$28.8B$29.2B+1.4%
2024-10-30$3.40$4.16+22.4%$28.7B$29.4B+2.5%
2024-07-31$5.85$6.96+19.0%$28.5B$29.5B+3.6%
2024-04-24$6.12$7.23+18.1%$28.5B$29.6B+3.8%
2024-01-25$-0.07$-0.11−57.1%$25.5B$26.5B+3.6%
2023-11-01$7.16$7.78+8.7%$25.6B$26.4B+3.4%
2023-08-02$8.82$8.94+1.4%$26.2B$26.7B+2.0%
2023-04-26$9.27$9.38+1.2%$26.2B$26.7B+2.1%
2023-02-01$1.46$1.62+11.0%$22.5B$22.4B−0.2%
2022-11-02$6.28$6.88+9.6%$22.8B$22.8B−0.1%
2022-07-27$7.67$8.67+13.0%$23.4B$23.7B+0.9%
2022-04-27$6.78$8.04+18.6%$23.5B$24.0B+1.8%
2022-02-02$1.23$1.24+0.8%$23.4B$21.1B−9.9%
2021-11-03$4.61$4.83+4.8%$20.9B$20.7B−0.9%
2021-07-28$6.86$6.89+0.4%$20.9B$20.6B−1.0%
2021-04-28$7.06$7.67+8.6%$18.9B$20.7B+9.5%
2021-02-03$-2.35$-2.30+2.1%$19.6B$19.1B−2.9%
2020-08-05$10.27$12.56+22.3%$15.5B$19.1B+22.8%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
0.706-150.806-220.806-290.607-060.807-130.507-201.407-270.808-030.608-100.608-170.608-240.508-31
Week ofNotionalSharesTrades
2026-08-31$499.2M1,250,76848,106
2026-08-24$604.1M1,553,77151,265
2026-08-17$622.0M1,632,76648,256
2026-08-10$554.3M1,442,74443,804
2026-08-03$788.6M2,143,76958,260
2026-07-27$1.4B3,635,72473,460

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1552.1%
DateShort shareShort volumeTotal volume
2026-10-1552.1%215,886414,663
2026-10-1453.9%256,740476,020
2026-10-1352.7%429,929815,624
2026-10-1244.9%356,723794,086
2026-10-0948.3%1,230,9052,549,409
2026-10-0845.2%408,747904,396
2026-10-0752.9%369,376697,830
2026-10-0669.1%501,848725,873
2026-10-0560.8%338,732557,393
2026-10-0262.6%184,620294,691
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
-1.2Jan-1.9Feb+0.0Mar+0.8Apr+3.9May-0.2Jun-0.3Jul+4.1Aug-1.4Sep+3.3Oct+1.4Nov+0.8Dec
MonthAvg returnUp yearsYears
Jan−1.2%60%20
Feb−1.9%40%20
Mar+0.0%52%21
Apr+0.8%50%20
May+3.9%55%20
Jun−0.2%75%20
Jul−0.3%55%20
Aug+4.1%80%20
Sep−1.4%50%20
Oct+3.3%60%20
Nov+1.4%45%20
Dec+0.8%50%20
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1454.3
MFI47.4
ADX23.0
Stochastic %K / %D60.1 / 62.9
Williams %R-53.5
CCI72
TSI / signal16.8 / 9.8
Chaikin money flow-0.27
ATR$18.37
Bollinger width20.2%
Volume vs 20-day avg0.68x
SupertrendUp

Moving averages and bands

level (price vs level)
SMA 20$399.02 (+3.6%)
SMA 50$393.92 (+4.9%)
SMA 200$300.98 (+37.3%)
EMA 21$405.79 (+1.9%)
EMA 50$393.84 (+4.9%)
EMA 200$332.38 (+24.4%)
Bollinger upper$439.39 (−5.9%)
Bollinger lower$358.64 (+15.2%)
Parabolic SAR$383.61 (+7.7%)
Open the live chart, 110+ indicators

About Humana Inc.

Humana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services. The firm provides a wide array of medical and supplementary insurance plans directly to individual consumers. Furthermore, Humana collaborates with government entities; it holds a contract with the Centers for Medicare and Medicaid Services (CMS) to manage the Limited Income Newly Eligible Transition (LI NET) prescription drug program. The company also secures agreements with numerous states to deliver Medicaid, dual-eligible, and long-term care support benefits. For employer groups and individuals, Humana furnishes fully insured commercial medical and specialized health coverage, which encompasses dental, vision, and other ancillary health benefits. They additionally offer administrative services only (ASO) solutions and extend support to military personnel through contracts like the TRICARE T2017 East Region. Beyond insurance products, the company delivers comprehensive healthcare services directly. These include pharmacy management, provider network services, and a suite of home-based solutions such as home health care, serving both its own health plan enrollees and external clients. By the close of 2021 (December 31), Humana's reach extended to approximately 17 million individuals enrolled in its medical benefit plans and an additional 5 million utilizing its specialized product offerings. Established in 1961, Humana Inc. maintains its corporate headquarters in Louisville, Kentucky.

https://www.humana.com

Key executives

NameTitlePayBorn
Celeste MelletChief Financial Officer$8.3M1977
Japan MehtaChief Information Officer$5.7M1981
James A. RechtinPresident, Chief Executive Officer & Director$4.9M1971
Michelle O'HaraChief Human Resources Officer$4.1M1976
Bruce Dale BroussardStrategic Advisor$4.1M1962
George RenaudinStrategic Advisor$4.1M1969
Sanjay K. ShettyPresident of CenterWell$2.1M1974
Joseph C. VenturaChief Legal Officer$840,3591977

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
Celeste M. Mellet Chief Financial Officer2025$900,000$10.7M$1.3M$18.9M
James A. Rechtin President and Chief Executive Officer2025$1.3M$13.9M$3.0M$18.8M
Japan A. Mehta Chief Information Officer2025$618,750$3.9M$732,787$9.6M
Michelle A. O’Hara Chief Human Resources Officer2025$715,385$4.9M$840,000$8.9M
Sanjay K. Shetty, M.D. President, CenterWell2025$715,769$5.1M$963,335$7.2M
Susan M. Diamond Former Chief Financial Officer2025$961,075$0$1.2M$2.4M

Employees

42k201846k201949k202096k202167k202268k202366k202467k2025

Dividends

Ex-dateAmountPaid
2026-10-30$0.8852026-11-27
2026-06-26$0.8852026-07-31
2026-03-27$0.8852026-04-24
2025-12-26$0.8852026-01-30
2025-09-26$0.8852025-10-31
2025-06-27$0.8852025-07-25
2024-12-31$0.8852025-01-31
2024-09-30$0.8852024-10-25

Moat model

Weak · Efficient Scale · 2026-06-30
Cost advantage49
Intangibles28
Switching costs48
Network effect45
Efficient scale68
Our component scores (0-100) and overall 45.8; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms